CLINICAL TRIALS AT ENANTA

Enanta is committed to developing new treatments for viral infections and liver diseases. Enanta has active research and development programs in areas such as Non-Alcoholic Steatohepatitis, (NASH), Primary Biliary Cholangitis, (PBC), Respiratory Syncytial Virus, (RSV) and Hepatitis B Virus (HBV).

If you are a healthcare professional interested in learning more about Enanta’s clinical trials, please contact: Nathalie Adda, MD at nadda@enanta.com.

Learn more about any of our clinical trials described below by clicking the ClinicalTrials.gov. identifier listed below the description of the trial.


Primary Biliary Cholangitis

A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Clinicaltrials.gov identifier: NCT03394924


Non-Alcoholic Steatohepatitis

A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Clinicaltrials.gov identifier: NCT03421431

Respiratory Syncytial Virus

A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-938 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-938 Pharmacokinetics in Healthy Subjects
Clinicaltrials.gov identifier: NCT03384823